Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| AHMA | Ambitions Enterprise Management L.l.c | $2.43 | -$2.12 | -46.53% | 1.4M | $134M | $1.10$39.50 |
| VALN | Valneva Se | $6.50 | -$3.82 | -37.02% | 28.4K | $888M | $5.43$12.25 |
| AREB | American Rebel | $6.46 | -$2.75 | -29.86% | 74.9K | $69M | $6.20$835,600.00 |
| WSHP | WeShop | $8.34 | -$3.33 | -28.54% | 965.7K | $274M | $7.11$250.00 |
| ANNA | AleAnna | $5.26 | -$1.81 | -25.60% | 180.9K | $287M | $2.31$18.30 |
| SWMR | Swarmer | $27.53 | -$9.19 | -25.02% | 4.4M | $453M | $5.00$65.04 |
| ATLN | Atlantic International | $3.65 | -$0.80 | -17.98% | 3.4K | $279M | $1.16$6.10 |
| CODX | Co-Diagnostics | $2.15 | -$0.45 | -17.18% | 982.2K | $5.4M | $2.05$46.50 |
| ARBB | Arb Iot Group | $4.35 | -$0.82 | -15.78% | 11.9K | $9.1M | $3.92$16.35 |
| ACXP | Acurx Pharmaceuticals | $4.73 | -$0.88 | -15.63% | 557.4K | $16M | $1.33$21.00 |
| ROMA | Roma Green Finance | $5.93 | -$1.01 | -14.55% | 32.1K | $413M | $0.72$8.88 |
| SBDS | Solo Brands | $3.53 | -$0.51 | -12.62% | 62.9K | $6.7M | $0.54$23.20 |
| NERV | Minerva Neurosciences | $6.63 | -$0.91 | -12.07% | 281.7K | $326M | $1.15$12.46 |
Related Articles
Featured Article
Thinking About Buying Swarmer After Its Explosive IPO? Here Are 3 Things Investors Need to Know.
Jack Delaney|Mar 21, 2026
Don't let the fear of missing out drive your investing decision.
Is This New Data on Valneva's Less-Effective Booster Concerning?
Keith Speights and Brian Orelli, PhD|Dec 18, 2021
Some recent dismal results for Valneva's vaccine looked bad. But there could be more to the story.
2 Stocks That Could Soar With the Emergence of the Omicron Variant
Keith Speights and Brian Orelli, PhD|Dec 12, 2021
It's too soon to know what the full impact of omicron will be. But these vaccine makers could be particular winners.
These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday
Dan Caplinger|Oct 18, 2021
The Nasdaq looks poised to open slightly lower after a strong week.
Co-Diagnostics: Buy the Dip?
Cory Renauer|Mar 29, 2021
Analysts following this coronavirus stock have darkened their post-pandemic outlook.
What Investors Didn't Like About Co-Diagnostics' Q4 Update
Keith Speights|Mar 26, 2021
The company missed earnings expectations and hinted at slowing growth in 2021.
Co-Diagnostics Names New CFO and CSO
Eric Volkman|Feb 23, 2021
With the latter appointment, the company's founder moves into a more advisory role.
Up 938% in 2020, Is Co-Diagnostics Still a Buy in 2021?
Taylor Carmichael|Jan 30, 2021
This diagnostic specialist started off the year as a micro cap, but it roared ahead with its COVID-19 test.
Forget Snowflake! Buy This Ultra-High-Growth Stock
Jason Hawthorne|Jan 15, 2021
This business came into 2020 as an unknown, and now it's generating so much growth it makes even high-profile IPOs look like they're standing still.
These Were the 3 Best Coronavirus Stocks of 2020
Keith Speights|Jan 1, 2021
Not all of them were COVID-19 vaccine makers.
